Regulatory News:
BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment
and supportive care of cancer and AIDS patients, has presented results
on miconazole Lauriad® at the 47th Annual Meeting
of the Infectious Diseases Society of America (IDSA) in Philadelphia
(October 29 – November 1st).
The additional results from BioAlliance Pharma’s pivotal Phase III study
with miconazole Lauriad® mucoadhesive buccal tablets (MBT)
demonstrated comparable efficacy and safety profile to that of
clotrimazole troches (administered five times per day) for oropharyngeal
candidiasis (OPC), in HIV-positive patients in 40 sites in the United
States, Canada and South Africa. The data also demonstrated a good
patient compliance as a result of the added convenience of a once-a-day
dosing.
This presentation was given by Dr Rajesh V. Lalla, oral medicine
specialist, from the University of Connecticut Health Center.
OPC, also known as thrush, is an oral fungal infection most common in
individuals with weakened immune systems – particularly those with
HIV/AIDS and those undergoing cancer treatments. OPC is a disruptive
condition that results in lesions and inflammation in the mouth, and
includes symptoms such as soreness, burning and/or altered taste.
About IDSA
The Infectious Diseases Society of America (IDSA) represents physicians,
scientists and other health care professionals who specialize in
infectious diseases. IDSA’s purpose is to improve the health of
individuals, communities, and society by promoting excellence in patient
care, education, research, public health, and prevention relating to
infectious diseases.
About BioAlliance Pharma
As a preferred partner for hospital-based specialists, BioAlliance
Pharma is a company which develops and markets innovative products in
France, especially in the fields of opportunistic infections and
chemotherapy complications. In areas where medical needs are
insufficiently met, our targeted approaches help overcome drug
resistance and improve patient health & quality of life. BioAlliance
Pharma’s ambition is to become a leading player in these fields by
coupling innovation to patient needs.
For more information, visit the BioAlliance Pharma web site at
http://www.bioalliancepharma.com
.
Disclaimer
This communication expressly or implicitly contains certain
forward-looking statements concerning BioAlliance Pharma SA and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors, which could cause the actual results,
financial condition, performance or achievements of BioAlliance Pharma
SA to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
BioAlliance Pharma SA is providing this communication as of this date
and does not undertake to update any forward-looking statements
contained herein as a result of new information, future events or
otherwise.
For a discussion of risks and uncertainties which could cause actual
results, financial condition, performance or achievements of BioAlliance
Pharma SA to differ from those contained in the forward-looking
statements, please refer to the Risk Factors ("Facteurs de Risque")
section of the 2008 Reference Document filed with the AMF on April 7,
2009, which is available on the AMF website (
http://www.amf-france.org
)
or on BioAlliance Pharma S.A.'s website (
http://www.bioalliancepharma.com
).
BioAlliance Pharma SA
Dominique Costantini MD,
President and CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com
or
Nicolas
Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com
or
ALIZE
RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com
